212Pb AR RMX

N/A

Report date: 2025/11/20 11:38:05
NME

Base Information

Drug Name212Pb AR RMX
Drug Alias Name212Pb-AR-RMXLead-212 radionuclide212-Pb-Targeted-Alpha-Emmitter-Therapy212Pb-somatostatin analogs212Pb-octreotate analog +[11] 
ClassificationDiagnostic agent (In vivo)Radiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lead > 212Pb +[5] 
Mechanisms of ActionSomatostatin receptor modulatorsIonising radiation emitters
TargetsSomatostatin receptor
Therapy Area/IndicationsGastroenteropancreatic neuroendocrine tumorCarcinoma, NeuroendocrineNeuroendocrine Tumors
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesOrano Med LlcRadiomedix Inc
China Registration ClassN/A

Develop Information

Active CompaniesOrano Med LlcSanofiRadiomedix Inc
Inactive CompaniesN/A
Active IndicationsGastroenteropancreatic neuroendocrine tumorCarcinoma, NeuroendocrineNeuroendocrine Tumors
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A